Adenosine Receptor
P1 receptor
Adenosine receptors (ARs) comprise a group of G protein-coupled receptors (GPCR) which mediate the physiological actions of adenosine. To date, four AR subtypes have been cloned and identified in different tissues. These receptors have distinct localization, signal transduction pathways and different means of regulation upon exposure to agonists. A key property of some of Adenosine receptors is their ability to serve as sensors of cellular oxidative stress, which is transmitted by transcription factors, such as NF-κB, to regulate the expression of ARs. The importance of Adenosine receptors in the regulation of normal and pathological processes such as sleep, the development of cancers and in protection against hearing loss will be examined.
Adenosine Receptor Isoform Specific Products
All Product Categories
-
Adenosine Receptor Inhibitors
(41)
View all products
-
Adenosine Receptor Agonists
(119)
View all products
-
Adenosine Receptor Antagonists
(203)
View all products
-
Adenosine Receptor Activators
(9)
View all products
-
Adenosine Receptor Modulators
(11)
View all products
-
Adenosine Receptor Degrader
(1)
View all products
-
Adenosine Receptor Ligands
(13)
View all products
-
Adenosine Receptor Related Products (428)
Related Products (428)
-
Antibodies (2)
-
Adenosine Receptor Isoform Comparison
-
Binodenoson (Standard)
0 ImagesCat. No.: HY-106450RCAS No.: 144348-08-3Synonyms: MRE-0470 (Standard); WRC 0470 (Standard)Binodenoson (Standard) is the analytical standard of Binodenoson (HY-106450). This product is intended for research and analytical applications. Binodenoson (MRE-0470) is a potent and selective A2A adenosine receptor agonist (KD=270 nM). Binodenoson is being developed as a short-acting coronary vasodilator as an adjunct to radiotracers for use in myocardial stress imaging.
-
Alloxazine (Standard)
0 ImagesCat. No.: HY-123085RCAS No.: 490-59-5Synonyms: Isoalloxazine (Standard)Alloxazine (Standard) is the analytical standard of Alloxazine. This product is intended for research and analytical applications. Alloxazine is a selective A2b antagonist. Alloxazine completely block 5’N-Ethylcarboxamido adenosine (NECA)-mediated cyclic AMP accumulation with an IC50 of 2.9 μM. Alloxazine can be used for the research of cancer.
-
MRS 1754 (Standard)
0 ImagesMRS 1754 (Standard) is the analytical standard of MRS 1754. This product is intended for research and analytical applications. MRS 1754 is a selective antagonist radioligand for A2B adenosine receptor with very low affinity for A1 and A3 receptors of both humans and rats.
-
MRS-1706 (Standard)
0 ImagesCat. No.: HY-103186RCAS No.: 264622-53-9MRS-1706 (Standard) is the analytical standard of MRS-1706. This product is intended for research and analytical applications. MRS-1706 is a potent and selective adenosine A2B receptor inverse agonist. MRS-1706 has Ki values of 1.39, 112, 157, and 230 nM for human A2B, A2A, A1 and A3 receptors respectively. MRS-1706 blocks adenosine-mediated cAMP induction.
-
Dansyl-NECA
0 ImagesCat. No.: HY-110170CAS No.: 219982-12-4Dansyl-NECA (compound 1) is a dansyl-labeled adenosine receptor antagonist.
-
DPCPX (Standard)
0 ImagesSynonyms: PD 116948 (Standard)DPCPX (Standard) is the analytical standard of DPCPX. This product is intended for research and analytical applications. DPCPX (PD 116948), a xanthine derivative, is a highly potent and selective Adenosine A1 receptor antagonist, with a Ki of 0.46 nM in 3H-CHA binding to A1 receptors in rat whole brain membranes.
-
Namodenoson (Standard)
0 ImagesSynonyms: CF-102 (Standard); 2-Cl-IB-MECA (Standard)Namodenoson (Standard) is the analytical standard of Namodenoson. This product is intended for research and analytical applications. Namodenoson (CF-102) is a selective A3 adenosine receptor (A3AR) agonist (Ki=0.33 nM). Namodenoson displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively.
-
A2AAR antagonist 1
0 ImagesCat. No.: HY-151387CAS No.: 1784491-64-0A2AAR antagonist 1 (compound 21a) is an A2AAR (adenosine A2A receptor) antagonist with a Ki value of 20 nM. A2AAR antagonist 1 shows high ligand efficiency, and it can be used for the research of neurodegenerative diseases.
-
Benzo[c][1,8]naphthyridin-6(5H)-one
![Benzo[c][1,8]naphthyridin-6(5H)-one](https://file.medchemexpress.com/product_pic/hy-115862.gif "Click to View Benzo[c][1,8]naphthyridin-6(5H)-one Product Detail")
0 ImagesCat. No.: HY-115862CAS No.: 53439-81-9Benzo[c][1,8]naphthyridin-6(5H)-one exhibits low micromolar affinity to human adenosine receptor (AR) A1 and hA2A, with Ki of 4.6 and 4.8 μM. Benzo[c][1,8]naphthyridin-6(5H)-one is inhibitor for poly ADP-ribose polymerase-1 (PARP-1) and aurora kinase A, with IC50 of 0.311 and 5.5 μM.
-
N6-(2-Phenylethyl)adenosine (Standard)
0 ImagesCat. No.: HY-101854RCAS No.: 20125-39-7Synonyms: N6-Phenethyladenosine (Standard); N6-Phenylethyladenosine (Standard)N6-(2-Phenylethyl)adenosine (Standard) (N6-Phenethyladenosine (Standard)) is the analytical standard of N6-(2-Phenylethyl)adenosine (HY-101854). This product is intended for research and analytical applications. N6-(2-Phenylethyl)adenosine (N6-Phenethyladenosine), an adenosine derivative, is a potent adenosine receptors (AR) agonist with Ki values of 11.8 nM, 30.1 nM, 0.63 nM for rat A1AR, human A1AR and hA3AR, respectively.
-
Adenosine monophosphate-13C10,15N5
0 ImagesCat. No.: HY-A0181S6Synonyms: AMP-13C10,15N5Adenosine monophosphate-13C10,15N5 (AMP-13C10,15N5) is the 13C- and 15N-labeled Adenosine monophosphate (HY-A0181). Adenosine monophosphate is an adenosine A1 receptor agonist. Adenosine monophosphate has significant antiviral activity against HSV-1 and HSV-2. Adenosine monophosphate is a key cellular metabolite regulating energy homeostasis and signal transduction.
-
CVT-2759 analog
0 ImagesCat. No.: HY-123127CAS No.: 342419-10-7CVT-2759 analog (compound 15) is a partial agonist of A1 adenosine receptor (Ki=167 nM) and can be used for the study of cardiac arrhythmias.
-
Propentofylline-d6
0 ImagesCat. No.: HY-107203SCAS No.: 1216516-37-8Synonyms: HWA 285-d6Propentofylline-d6 (HWA 285-d6) is the deuterium labeled Propentofylline. Propentofylline is an orally active and brain-penetrant phosphodiesterase inhibitor. Propentofylline blocks adenosine reuptake and prevents cyclic nucleotide degradation. Propentofylline can be used for the research of primary degenerative (Alzheimer's) dementia, vascular dementia, cerebral ischemia, acute stroke, and learning and memory disorders.
-
LUF5981
0 ImagesCat. No.: HY-111088CAS No.: 929641-63-4LUF5981 is a relatively potent adenosine A2A receptor (A2A) antagonist with pIC50 value of 6.7.
-
Doxofylline (Standard)
0 ImagesDoxofylline (Standard) is the analytical standard of Doxofylline. This product is intended for research and analytical applications. Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation). Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm.
-
CCPA (Standard)
0 ImagesCat. No.: HY-103185RCAS No.: 37739-05-2Synonyms: 2-Chloro-N6-cyclopentyladenosine (Standard)CCPA (2-Chloro-N6-cyclopentyladenosine (Standard)) is the analytical standard of CCPA (HY-103185). This product is intended for research and analytical applications. CCPA (2-Chloro-N6-cyclopentyladenosine) a highly selective A1 adenosine receptors agonist with a Ki of 0.4 nM. CCPA inhibits adenylate cyclase with an IC50 of 33 nM. CCPA exhibits anti-seizure and cardiacprotective activity. CCPA can be used for the research of seizure and myocardial infarction.
-
CGS 15943 (Standard)
0 ImagesCat. No.: HY-100678RCAS No.: 104615-18-1CGS 15943 (Standard) is the analytical standard of CGS 15943. This product is intended for research and analytical applications. CGS 15943 is an orally bioavailable non-xanthine Adenosine Receptor antagonist. Its Ki for human A1, A2A, A2B, and A3 Adenosine Receptors are 3.5, 4.2, 16, and 50 nM in transfected CHO cells, respectively. .
